A vs ABCL
Agilent Technologies vs AbCellera Biologics Inc. — AI-powered side-by-side comparison
A
Agilent Technologies
59
Buy
VS
ABCL
AbCellera Biologics Inc.
66
Buy
| Metric | A | ABCL |
|---|
| AI Score |
59
|
66
|
| Price |
$156.25
|
$12.50
|
| P/E Ratio |
30.75×
|
-19.65×
|
| ROE |
19.3%
|
-15.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
53.0%
|
75.0%
|
| Debt / Equity |
0.47×
|
0.15×
|
| Dividend Yield |
0.7%
|
0.0%
|
| RSI (14) |
61.3
|
59.2
|
| Beta |
1.229
|
1.191
|
| Expected Upside |
+0.2%
|
—
|
AI Committee View
Current Innellis committee reasoning for A versus ABCL.
ABCL leads by 7 points.
ABCL scores 66/100 (Buy) versus A at 59/100 (Buy).
A Committee View
67% agreement
6 analysts
The primary driver is price structure making higher highs and higher lows. The main limiting factor is bollinger bandwidth of 17.4% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 20.8% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.4 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Bollinger bandwidth of 17.4% signals elevated volatility — Risk
ABCL Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 120.7% signals elevated volatility — Risk